We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Are AstraZeneca plc & Thomas Cook Group plc ‘Screaming Buys’?

Should you buy AstraZeneca plc (LON: AZN) and Thomas Cook Group plc (LON: TCG) right now?

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

In the long run, all companies encounter highly challenging periods. They can be due to external factors such as a weakening in demand for a particular product or a slowdown in the wider economy. They can also be caused by internal challenges, such as poor planning and a strategy which ultimately leads to disappointing top and bottom line performance.

Either way, it normally has a very negative impact on a company’s share price and, while the effects can be horrific for investors, it also presents a very appealing buying opportunity. That’s because if the company can either adopt a better strategy or the external factors improve, capital gains could prove to be very enticing.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

One company which has endured a very tough period is AstraZeneca (LSE: AZN). Its problems have largely been its own making, with the company failing to develop sufficient new drugs and put in place a suitable pipeline to overcome the inevitable loss of patents on key, blockbuster drugs. Furthermore, it also failed to use its cash in the most efficient manner; favouring a share buyback programme ahead of investing in research and development capabilities.

The result has been a severe decline in profitability, with AstraZeneca’s earnings per share expected to be just 62% of their 2011 level when the company reports its 2015 full-year results. However, AstraZeneca appears to now be making all of the right moves through which to mount a successful comeback, with an ambitious acquisition programme breathing new life into the company’s pipeline.

Clearly, it will inevitably take time to post positive profit growth. However, it seems likely to do so over the medium term which makes it current price to earnings (P/E) ratio of 16.1 seem hugely appealing.

Similarly, Thomas Cook (LSE: TCG) has also endured a troubled past, with the company becoming a loss-making entity in the period 2011 to 2014. This had a disastrous impact on the company’s share price, with it falling to a low of 13p in 2012 and there being major concerns about whether it would survive its difficult trading period.

However, now that the economic outlook is improved Thomas Cook is moving from strength to strength. Today’s results show that the company has made its first annual profit in five years despite the negative impact on demand for its holidays caused by the terrorist incidents of recent months. And, with the winter season already being 58% sold, it appears to be well-placed to deliver continued strong performance moving forward.

Looking ahead, Thomas Cook is forecast to increase its earnings by 28% next year which, alongside a P/E ratio of 9.4, puts it on a price to earnings growth (PEG) ratio of just 0.3. This indicates that its shares have very appealing capital gains prospects – especially since the UK and European economies are showing signs of life and are set to benefit from a continued loose monetary policy in future years.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Array of piggy banks in saturated colours on high colour contrast background
Investing Articles

How have Legal & General shares become a dividend powerhouse? 5 reasons why!

Legal & General shares have carried an average dividend yield above 8% since 2015! What makes them so great? And…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

2 FTSE 100 bargain stocks to buy in June?

Searching for the best value stocks to buy? Royston Wild reveals two trading on rock-bottom valuations -- including a popular…

Read more »

Illustration of flames over a black background
Investing Articles

Hot, hotter, hottest. Is it too late to consider these 3 FTSE 100 shares?

James Beard looks at the three best- performing FTSE 100 stocks over the past year. But are they still worth…

Read more »

Young female analyst working at her desk in the office
Investing Articles

The only FTSE 100 stock I own right now

Muhammad Cheema reveals the only share he owns in the FTSE 100. However, that doesn’t mean he’s not a fan…

Read more »

Investing Articles

Are Greggs shares about to go gangbusters all over again?

Greggs shares have been showing signs of renewed life and Harvey Jones examines whether the battered FTSE 250 bakery chain…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

4,898 shares in British American Tobacco return £12,000 a year in dividends. Worth it?

A falling share price means a higher dividend yield for British American Tobacco shares. Should passive income investors take a…

Read more »

A handsome mature bald bearded black man in a sunglasses and a fashionable blue or teal costume with a tie is standing in front of a wall made of striped wooden timbers and fastening a suit button
Growth Shares

As it swallows up more firms, this penny stock looks primed to head higher

Jon Smith reviews a penny stock that has caught his attention, with its acquisition strategy proving to help increase the…

Read more »

Array of piggy banks in saturated colours on high colour contrast background
Investing Articles

£5,000 invested in HSBC shares in an ISA 5 years ago is now worth…

HSBC has made for a stunning investment. Andrew Mackie assesses whether new ISA investors could still see similar returns over…

Read more »